BridgeMD
New treatment option for Exfoliation Glaucoma
Official title Comparison Of iStent to Laser in Exfoliation Glaucoma Helsinki Study Group
ClinicalTrials.gov ID: NCT04635020
What this study is testing
- What it's testing
- The purpose of the study is to investigate the efficacy of an iStent trabecular microbypass stent compared to selective laser trabeculoplasty in combination with cataract surgery in eyes with exfoliation glaucoma (EXF)
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 50 to 100
You may be able to join if
- Signed consent of information
- Clinical significant cataract
- Able to attend 12 month period
- Mild to moderate exfoliation glaucoma according to European glaucoma society guidelines (EGS)
- Group I stable glaucoma (IOP within individual target IOP), and group II unstable glaucoma (IOP above individual target IOP) with baseline glaucoma...
You likely can't join if
- Clinical set target IOP \< 16 mmHg in advanced glaucoma
- Baseline IOP prior to enrolment ≥30 mmHg, and ≥3 glaucoma medications
- Closed angle
- Congenital angle anomaly
- Clinically significant corneal dystrophy or other hindering corneal condition
- Unable to use topical medical therapy
See the full eligibility criteria
- Signed consent of information
- Clinical significant cataract
- Able to attend 12 month period
- Mild to moderate exfoliation glaucoma according to European glaucoma society guidelines (EGS)
- Group I stable glaucoma (IOP within individual target IOP), and group II unstable glaucoma (IOP above individual target IOP) with baseline glaucoma medication
- Target IOP ≥16
- Able to understand Finnish, Swedish or English
- Clinical set target IOP \< 16 mmHg in advanced glaucoma
- Baseline IOP prior to enrolment ≥30 mmHg, and ≥3 glaucoma medications
- Closed angle
- Congenital angle anomaly
- Clinically significant corneal dystrophy or other hindering corneal condition
- Unable to use topical medical therapy
- Central corneal thickness of less than 480um or more than 620um
- Active uveitis, cystic macular edema (CME), exudative age-related macular degeneration, proliferative diabetic retinopathy or clinical significant macular edema, intraocular neoplasm, intraocular injections, intraocular...
- Previous intraocular surgery, refractive surgery or cycloablation
- Two or more prior SLT or laser trabeculoplasty
- Unable to participate due to another medical disease or condition
- Participating in another clinical trial
The study team makes the final eligibility decision.
Where it's taking place
- Helsinki, Finland
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 50 years to 100 years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Helsinki, Finland. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.